Decoy Therapeutics Inc.
DCOY
$5.15
-$0.29-5.33%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.73M | 5.14M | 5.18M | 5.58M | 5.46M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.10M | 5.57M | 5.68M | 6.18M | 6.23M |
| Operating Income | -4.10M | -5.57M | -5.68M | -6.18M | -6.23M |
| Income Before Tax | -12.52M | -5.00M | -5.10M | -5.57M | -5.58M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.52 | -5.00 | -5.10 | -5.57 | -5.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.52M | -5.00M | -5.10M | -5.57M | -5.58M |
| EBIT | -4.10M | -5.57M | -5.68M | -6.18M | -6.23M |
| EBITDA | -4.09M | -5.56M | -5.68M | -6.18M | -6.23M |
| EPS Basic | -37.20 | -18.32 | -13.74 | -9.16 | -4.58 |
| Normalized Basic EPS | -0.75 | -3.84 | -3.84 | -3.84 | -3.84 |
| EPS Diluted | -37.20 | -18.32 | -13.74 | -9.16 | -4.58 |
| Normalized Diluted EPS | -0.75 | -3.84 | -3.84 | -3.84 | -3.84 |
| Average Basic Shares Outstanding | 382.70K | 319.60K | 319.60K | 319.60K | 319.60K |
| Average Diluted Shares Outstanding | 1.34M | 1.28M | 958.80K | 639.20K | 319.60K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |